Pharma BD Deal Intelligence
Abbott's $6.2B Solvay acquisition was a mixed bag: Creon became a durable ~80% share pancreatic enzyme franchise still growing in 2020, but TriCor/Trilipix fell 29% in Q1 2013 to generics and AndroGel drew a decade-long FTC pay-for-delay case (vacated in 2020, no payment made). All assets survived into the 2013 AbbVie spinoff intact, with no outright divestitures.
One durable winner (Creon), one patent-cliff casualty (TriCor/Trilipix), and a decade of antitrust litigation on AndroGel that was ultimately reversed but never turned into upside.
Full analysis, sources & comparables →Total consideration €5.2B (€4.5B upfront cash + up to €300M milestones 2011-2013 + ~€400M assumed liabilities); expected to add $0.10 EPS in 2010, increasing…
Abbott CEO Miles White: 'The acquisition of Solvay Pharmaceuticals is a key part of Abbott's strategy to bolster our presence in key markets and deliver…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Abbott completed acquisition of Solvay's pharmaceuticals unit for $6.2B (€4.5B), expanding emerging markets and pharmaceutical product portfolio. Deal originally announced 2009, closed February 2010.
One durable winner (Creon), one patent-cliff casualty (TriCor/Trilipix), and a decade of antitrust litigation on AndroGel that was ultimately reversed but never turned into upside.
Assessment window: 15yr post-close.
$2.9B Solvay Rx 2010 contribution to Abbott sales
Solvay's pharma portfolio spanned three commercial spaces: cardiometabolic (TriCor/TriLipix fenofibrate franchise, AndroGel testosterone replacement), gastroenterology (Creon pancreatic enzyme replacement therapy for exocrine pancreatic insufficiency), and vaccines (Influvac seasonal flu vaccine plus a small portfolio of pediatric/specialty vaccines). The portfolio also included assets in Parkinson's disease, Meniere's disease/vertigo, and women's hormonal health.
The fenofibrate franchise (TriCor/TriLipix) competed with statins (Lipitor, Crestor) and other lipid-lowering agents but was the dominant fibrate brand in the US — Abbott already co-marketed it under a Solvay license, and a key driver of the deal was eliminating ~€500M in annual fenofibrate royalty payments (Datamonitor projected royalties to reach €880M by 2014, per https://www.chemistryworld.com/news/abbott-wins-the-race-for-solvays-pharma-business/3000261.article). AndroGel was the leading branded testosterone replacement therapy competing with Testim (Auxilium) and Axiron (Lilly). Creon was the dominant US PERT brand against Zenpep (Aptalis/Allergan/Forest) and Pancreaze (J&J). Influvac competed with Sanofi Pasteur's Fluzone and GSK's Fluarix in the global flu vaccine market. PharmaVentures' Nigel Borshell called the deal 'great' for Abbott given royalty elimination and emerging-markets reach. Datamonitor's Joshua Owide framed it as essential — without Solvay, Abbott's prescription business faced just 0.2% CAGR through 2014. Abbott later spun the pharma business into AbbVie (2013), and most Solvay-derived assets transferred with it.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Solvay Pharmaceuticals (this deal) | 2010 | $6.2B | 54 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2010 deals · Abbott Laboratories deals · Gastroenterology deals